Brief: Rvl Pharmaceuticals Plc Announces Preliminary Q4 Sequential Growth Of 21%
09/01/2023 12:57
Jan 9 (Reuters) - RVL Pharmaceuticals PLC RVLP.O :
* RVL PHARMACEUTICALS PLC ANNOUNCES PRELIMINARY FOURTH
QUARTER
SEQUENTIAL GROWTH OF 21% AND FULL YEAR 2022 UPNEEQ® NET PRODUCT
SALES
* RVL PHARMACEUTICALS PLC - EXPECTS Q4 2022 PRELIMINARY
UPNEEQ NET
PRODUCT SALES OF APPROXIMATELY $12.1 MILLION, REPRESENTING AN
INCREASE OF 21% OVER Q3 2022
Source text for Eikon: ID:nGNX7zttkh
Further company coverage: RVLP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RVL Pharmaceuticals
See all newsBrief: RVL Pharmaceuticals Says High Court Of Ireland Made A Winding Up Order In Respect Of Co On Feb 12
Brief: RVL Pharmaceuticals Says Co Issued Petition In Central Office Of High Court In Ireland To Wind Up Company
Brief: RVL Completes Financial Restructuring
Brief: Rvl Pharmaceuticals PLC Received Delisting Notice From Listing Qualifications Department Of Nasdaq Stock Market Llc
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius